Recent advancements in diabetes treatment have brought forth a new generation of drugs known as GLP-1 receptor agonists. These molecules work by mimicking the effects of glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar levels. Among the most promising recent GLP-1 receptor agonists are Retaglutide, Retatrutide, and Tirzepatide.